Table of Content
1. Report Prologue

2. Market Introduction

2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations

3. Research Methodology

3.1 Introduction
3.2 Primary Research
3.3 Secondary research
3.4 Market Size Estimation

4. Market Dynamics

4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment

5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis

6. Global Renal Disease Market, by Type

6.1 Introduction
6.2 Renal Disease Disease
6.2.1 Market Estimates & Forecast, 2023-2032
6.3 End-Stage Renal Disease
6.3.1 Market Estimates & Forecast, 2023-2032

7. Global Renal Disease Disease Market, by Treatment

7.1 Introduction
7.2 Dialysis
7.2.1 Market Estimates & Forecast, 2023-2032
7.3 Medication
7.3.1 Market Estimates & Forecast, 2023-2032
7.4 Kidney Transplantation
7.4.1 Market Estimates & Forecast, 2023-2032

8. Global Renal Disease Disease Market, by End User

8.1 Introduction
8.2 Dialysis Centers
8.2.1 Market Estimates & Forecast, 2023-2032
8.3 Hospital & Clinics
8.3.1 Market Estimates & Forecast, 2023-2032
8.4 Research and Academic Institutes
8.4.1 Market Estimates & Forecast, 2023-2032

9. Global Renal Disease Market, by Region

9.1 Introduction

9.2 Americas
9.2.1 North America
9.2.1.1 U.S.
9.2.1.1 Canada
9.2.2 South America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 U.K.
9.3.1.4 Italy
9.3.1.5 Spain
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Republic of Korea
9.4.6 Rest of Asia Pacific
9.5 The Middle East & Africa
9.5.1 United Arab Emirates
9.5.2 Saudi Arabia
9.5.3 Oman
9.5.4 Kuwait
9.5.5 Qatar
9.5.6 Rest of the Middle East & Africa

10 Company Landscape

10.1 Introduction
10.2 Market Share Analysis
10.3 Key Development & Strategies

11 Company Profiles

11.1 Abbott
11.1.1 Company Overview
11.1.2 Product Overview
11.1.3 Financials
11.1.4 SWOT Analysis
11.2 Amgen Inc.
11.2.1 Company Overview
11.2.2 Product Overview
11.2.3 Financial Overview
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.3 AstraZeneca
11.3.1 Company Overview
11.3.2 Product Overview
11.3.3 Financial Overview
11.3.4 Key Development
11.3.5 SWOT Analysis
11.4 Bristol-Myers Squibb Company
11.4.1 Company Overview
11.4.2 Product/Business Segment Overview
11.4.3 Financial Overview
11.4.4 Key Development
11.4.5 SWOT Analysis
11.5 Hoffmann-La Roche Ltd.
11.5.1 Company Overview
11.5.2 Product Overview
11.5.3 Financial overview
11.5.4 Key Developments
11.6 Pfizer Inc
11.6.1 Company Overview
11.6.2 Product Overview
11.6.3 Financial Overview
11.6.4 Key Developments
11.7 GlaxoSmithKline PLC
11.7.1 Overview
11.7.2 Product Overview
11.7.3 Financials
11.7.4 Key Developments
11.7.5 SWOT Analysis
11.8 Keryx Biopharmaceuticals, Inc.
11.8.1 Overview
11.8.2 Product Overview
11.8.3 Financials
11.8.4 Key Developments
11.8.5 SWOT Analysis
11.9 Kissei Pharmaceutical Co., Ltd.
11.9.1 Overview
11.9.2 Product Overview
11.9.3 Financials
11.9.4 Key Developments
11.9.5 SWOT Analysis
11.9 Novartis
11.9.1 Overview
11.9.2 Product Overview
11.9.3 Financials
11.9.4 Key Developments
11.9.5 SWOT Analysis
11.11 Others

12 Conclusion

12.1 Key Findings
12.1.1 From CEO’s View Point
12.1.2 Unmet Needs of the Market
12.2 Key Companies to Watch
12.3 Prediction of the Industry

13 Appendix